相关实验视频

Updated: Jan 7, 2026

Extraction and Quantification of Soluble, Radiolabeled Inositol Polyphosphates from Different Plant Species using SAX-HPLC

Extraction and Quantification of Soluble, Radiolabeled Inositol Polyphosphates from Different Plant Species using SAX-HPLC

Published on: June 26, 2020

伊诺西需要酶1α调解高血压和血管重塑

Keiichi Torimoto¹, Yuki Nakayama², Yuka Terada²

¹Cardiovascular Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, PA (K.T., K.O., S.C., S.E.).

Hypertension (Dallas, Tex. : 1979)

|December 30, 2025

概括

抑制需要内醇的酶1α (IRE1α) 会降低高血压和由血管酶II引起的血管变化. 这针对内质网膜压力,为高血压提供了潜在的治疗方法.

科学领域:

心血管生物学心血管生物学
分子医学是分子医学.
细胞内膜网膜应激压力

背景情况:

细胞内膜网膜 (ER) 应激和慢性未折叠蛋白反应 (UPR) 都与高血压有关.
需要内醇的酶1α (IRE1α) 是UPR的关键调解者.
IRE1α是管理高血压和相关血管并发症的潜在治疗标.

研究的目的:

调查抑制IRE1α是否可以缓解高血压和血管改造.
评估IRE1α抑制对血管光滑肌肉细胞功能的影响.
探索 IRE1α 在血管激素II 诱导的心血管变化的作用.

主要方法:

在C57BL6小鼠中输注 ангиотензинII,有或没有IRE1α抑制剂KIRA6.6.
评估血压,心血管改造和血管反应.
在老鼠血管光滑肌细胞中分析IRE1α激活,细胞内和分泌表型.

主要成果:

KIRA6治疗显著降低了血管新素II诱导的高血压.
血管加厚和周血管纤维化被KIRA6.6预防.
IRE1α抑制减轻了血管收缩,减少了细胞内Ca2+升高,并减轻了血管光滑肌细胞中独特的分泌表型.

结论:

准IRE1α是一种有前途的高血压治疗策略.
IRE1α抑制降低了血管抵抗和光滑肌肉细胞的Ca2+信号传递.
抑制IRE1α可以保护血管光滑肌细胞中的有害分泌表型,改善血管重塑.

关键词:

大动脉的动脉.血压血压血压血压纤维化纤维化这种高血压,高血压.伊诺西托尔 (英诺西托尔) 是一种内醇.

更多相关视频

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies

Precision Cut Lung Slices as an Efficient Tool for Ex vivo Pulmonary Vessel Structure and Contractility Studies

Published on: May 24, 2021

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

相关概念视频

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Hypertension II: Pathophysiology

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Hypertension and Regulation of Blood Pressure

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...